Clinical and pharmacological approaches to present-day influenza anti-viral therapy
https://doi.org/10.21518/2079-701X-2018-6-50-54
Abstract
Up to 646,000 people worldwide die from seasonal influenza-related respiratory illnesses each year. According to new estimates by WHO, the prevalence of three strains of the influenza virus is expected in the 2017-2018 epidemic season: Influenza A (H1N1), A (H3N2), and influenza B viruses. In this regard, the issue of prescribing rational etiotropic antiviral therapy becomes particularly topical. Neuraminidase inhibitors are currently the first line drugs that are recommended by WHO for the treatment and prevention of influenza.
About the Authors
N. B. Lazareva
Sechenov First Moscow State Medical University
Russian Federation
MD
Russian Federation
MD
M. B. Zuravleva
Sechenov First Moscow State Medical University
Russian Federation
MD
Russian Federation
MD
L. R. Panteleeva
Sechenov First Moscow State Medical University
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
References
1. Iuliano D, Roguski K, Chang Y et al. for the Global Seasonal Influenza-associated Mortality Collaborator Network. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study www.thelancet.com Published online December 13, 2017 http:// dx.doi.org/10.1016/S0140-6736(17)33293-2.
2. Tsvetkov VV, Golobokov GS. Neuraminidase inhibitors are the gold standard for type A antiviral therapy. Meditsinskiy Sovet, 2017, 4: 25-30
3. Orlova NV. Flu. Diagnosis, a strategy for selecting antiviral drugs. Meditsinskiy Sovet, 2017, 20: 80-86
4. Isayeva EI, Rovnova ZI, Polyakova TG, Vyazov SO. The frequency of detection of influenza virus antigens in peripheral blood lymphocytes of donors, depending on the epidemic activity of influenza A and B viruses. Voprosy Virusologii, 1993, 4: 146-9
5. Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza -recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 2011, 60: 1.
6. Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm.
7. Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats. J Infect Dis, 2011, 203: 6.
8. Dolin R. Resistance to neuraminidase inhibitors. Clin Infect Dis, 2011, 52: 438.
9. Guidelines on diagnosis and treatment of influenza. Ministry of Health of Russian Federation. 2017. 86 p.
10. Karpova LS, Popovtseva NM, Stolyarova TP, Stolyarov KA, Sominina AA, Burtseva EI. Analysis of the 2016 flu epidemic and the 2009 flu pandemic based on the data of two WHO National Centers in the Russian Federation. Epidemiologiya i Vaktsinoprofilaktika, 2016, 4 (89): 4-12
11. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. The Lancet, 2015, 385(9979): 1729–1737.
Review
For citations:
Lazareva NB, Zuravleva MB, Panteleeva LR. Clinical and pharmacological approaches to present-day influenza anti-viral therapy. Meditsinskiy sovet = Medical Council. 2018;(6):50-54. (In Russ.) https://doi.org/10.21518/2079-701X-2018-6-50-54
Views:
750
Email this article 